Oxford vaccine shot showed a strong response in older adults: study


The results of the Oxford Phase 2 study show that the vaccine is better tolerated in the elderly.

Oxford University confirmed in an early study that the Covid-19 vaccine, which it is developing with AstraZeneca Plc, elicits strong immune responses in older adults. The main results from the final phase of the studies are expected in the coming weeks.

The results, published Thursday in The Lancet Medical Journal, shed more light on preliminary data released in the past few months, showing that the experimental shot is one in older people who are at greatest risk for serious illness Triggered immune response. Researchers are still eagerly awaiting the results of late-stage studies that will show whether the Astra-Oxford vaccine can reach the bar set by front-runners Pfizer Inc. and Moderna Inc.

These results will follow a series of positive news on the vaccine front. Pfizer, who works with Germany’s BioNTech SE, said Wednesday that a final analysis of the trial data found the Covid vaccine to be 95% effective, paving the way for the company to get its first US approval for one in just a few days Apply for coronavirus shot. Moderna’s seems to be just as effective.

The results of the Oxford Phase 2 study show that the vaccine is better tolerated in the elderly and elicits a similar immune response in old and young adults. The study included 560 adults, including 240 over 70 years of age. This is evident from the results of older participants published last month and July data showing that the vaccine elicited robust immune responses in adults aged 18 to 55 years. Elderly patients have been hardest hit by the disease pandemic, with the vast majority of deaths occurring in those over 60.

“Inducing robust immune responses in older adults has been a longstanding challenge,” Angela Minassian, an Oxford investigator, wrote in a statement. “Evidence that this vaccine technology can trigger these reactions – in the age group most at risk of severe Covid-19 disease – gives hope that the vaccine’s effectiveness will be similar in younger and older adults.”


Oxford expects end-stage efficacy results in the coming weeks, according to a statement.

The study shows that the vaccine causes few side effects and elicits a response in T cells that target the virus within 14 days of the first dose and a protective antibody response within 28 days of the booster dose, the report said. In 208 out of 209 recipients, neutralizing values ​​were achieved 14 days after a boost vaccination.

(Except for the headline, this story was not edited by GossipMantri staff and posted from a syndicated feed.)


Please enter your comment!
Please enter your name here